These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33160046)

  • 1. Predictive identification of co-formers in co-amorphous systems.
    Chambers LI; Grohganz H; Palmelund H; Löbmann K; Rades T; Musa OM; Steed JW
    Eur J Pharm Sci; 2021 Feb; 157():105636. PubMed ID: 33160046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of molecular descriptors in the development of co-amorphous formulations.
    Meng-Lund H; Kasten G; Jensen KT; Poso A; Pantsar T; Rades T; Rantanen J; Grohganz H
    Eur J Pharm Sci; 2018 Jul; 119():31-38. PubMed ID: 29649569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
    Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
    Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptides as co-formers in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
    Wu W; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
    Wu W; Ueda H; Löbmann K; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
    Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers.
    Shete S; Reddy SC; Lakshman YD; Vullendula SKA; Mehta CH; Nayak UY; Dengale S
    Int J Pharm; 2021 Oct; 608():121119. PubMed ID: 34560205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.
    Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
    Molecules; 2015 Oct; 20(10):19571-87. PubMed ID: 26516832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.
    Nugrahani I; Jessica MA
    Molecules; 2021 May; 26(11):. PubMed ID: 34071731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
    Xiang TX; Anderson BD
    J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.
    Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T
    Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
    Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
    Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.